Oxford, 25 May 2011 – Chroma Therapeutics Limited announced today that it will report interim results from the OPAL Phase II study of its novel, orally-dosed anti-cancer agent tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held 3-7 June 2011, in Chicago, Illinois. This study has also been selected for an oral poster discussion session. Details of the presentations are as follows:
Abstract # 6517
Title: Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML.
Location and timing: Leukemia, Myelodysplasia, and Transplantation session, McCormick Place E450b, Friday 3 June 2011, 14:00–18:00 Central Time
Presenter: Dr Jorge Cortes (The University of Texas MD Anderson Cancer Center)
The poster will be included in a discussion session from 17:00-18:00 Central Time on Friday 3 June 2011 at McCormick Place Arie Crown Theater.
The abstract can be viewed on-line at the ASCO website: http://abstract.asco.org/AbstView_102_81627.html
The poster will be available at the company’s website, www.chromatherapeutics.com following the ASCO meeting.
Chroma Therapeutics Limited
Ian Nicholson Chief Executive Officer +44 (0)1235 829120
Richard Bungay Chief Financial Officer
Jon Coles +44 (0)20 7404 5959
AML is a haematologic cancer that is an aggressive, fast-growing cancer that starts inside the bone marrow with the production of abnormal blood cells. The American Cancer Society estimates that 12,330 new cases of acute myeloid leukemia (AML) will be diagnosed and approximately 8,950 deaths from AML will occur in the U.S. in 2010. AML is generally a disease of older people, with the average patient age at onset of approximately 67 years. There remain a substantial proportion of elderly patients who do not receive intensive chemotherapy due to their inability to tolerate such regimens, and other risk factors. Therefore, there is a significant unmet medical need in developing a well-tolerated and effective treatment for these patients.
Tosedostat (formerly CHR-2797) is an orally dosed aminopeptidase inhibitor which blocks the M1/17 family of aminopeptidases. Disrupting aminopeptidases deprives sensitive tumour cells of amino acids by blocking protein recycling, resulting in tumor cell death. Tosedostat has been studied in Phase I-II clinical trials both as a single agent and in combination with other chemotherapeutic agents. Such studies have demonstrated significant anti-tumour response without the typical side effects of conventional, non-targeted cytotoxic therapies. Initial target indications include AML, MDS and multiple myeloma. Tosedostat is licensed by Chroma from Vernalis and is partnered with CTI in the Americas. It has been granted orphan drug status for Acute Myeloid Leukaemia (AML) by both the Food and Drug Administration (FDA) and European Medicines Agency (EMA).”
About Chroma Therapeutics
Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Phase4 and The Wellcome Trust. More information about Chroma can be found at www.chromatherapeutics.com.